Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 7,400 shares, a decline of 23.7% from the October 15th total of 9,700 shares. Based on an average trading volume of 10,200 shares, the short-interest ratio is currently 0.7 days. Approximately 0.3% of the company’s stock are sold short.

Traws Pharma Stock Down 10.6 %

NASDAQ TRAW traded down $0.59 during mid-day trading on Friday, reaching $4.99. The stock had a trading volume of 5,965 shares, compared to its average volume of 5,875. Traws Pharma has a 1 year low of $4.44 and a 1 year high of $27.50. The firm has a market cap of $9.13 million, a P/E ratio of -0.04 and a beta of 1.41.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Thursday, August 15th. The company reported ($4.87) earnings per share (EPS) for the quarter. Traws Pharma had a negative return on equity of 144.95% and a negative net margin of 60,641.14%. The firm had revenue of $0.06 million during the quarter. As a group, equities analysts expect that Traws Pharma will post -146 earnings per share for the current fiscal year.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.